Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II) Article

cited authors

  • Hainsworth, John D.; Becker, Kevin P.; Mekhail, Tarek; Chowdhary, Sajeel A.; Eakle, Janice Faulkner; Wright, David; Langdon, Robert M.; Yost, Kathleen J.; Padula, Gilbert Darin Anthony; West-Osterfield, Kimberly; Scarberry, Meredith; Shaifer, Candice A.; Shastry, Mythili; Burris, Howard A., III; Shih, Kent

authors

Publication Date

  • September 1, 2019

webpage

published in

category

keywords

  • BKM120
  • Bevacizumab
  • Blood-brain barrier
  • Glioblastoma
  • PI3K pathway

start page

  • 303

end page

  • 311

volume

  • 144

issue

  • 2